Open AccessKSAC, the First Defined Polyprotein Vaccine Candidate for Visceral Leishmaniasis
Author(s) -
Yasuyuki Goto,
Ajay Bhatia,
Vanitha S. Raman,
Hong Liang,
Raodoh Mohamath,
Alessandro Picone,
Sílvia Vidal,
Thomas S. Vedvick,
Randall F. Howard,
Steven G. Reed
Publication year - 2011
Publication title -
clinical and vaccine immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.649
H-Index - 77
eISSN - 1556-6811
pISSN - 1556-679X
DOI - 10.1128/cvi.05024-11
Subject(s) - visceral leishmaniasis , leishmaniasis , antigen , leishmania , adjuvant , leishmania infantum , reverse vaccinology , immunology , virology , immune system , canine leishmaniasis , leishmania donovani , biology , medicine , epitope , parasite hosting , world wide web , computer science
A subunit vaccine using a defined antigen(s) may be one effective solution for controlling leishmaniasis. Because of genetic diversity in target populations, including both dogs and humans, a multiple-antigen vaccine will likely be essential. However, the cost of a vaccine to be used in developing countries must be considered. We describe herein a multiantigen vaccine candidate comprised of antigens known to be protective in animal models, including dogs, and to be recognized by humans immune to visceral leishmaniasis. The polyprotein (KSAC) formulated with monophosphoryl lipid A, a widely used adjuvant in human vaccines, was found to be immunogenic and capable of inducing protection against Leishmania infantum , responsible for human and canine visceral leishmaniasis, and against L. major , responsible for cutaneous leishmaniasis. The results demonstrate the feasibility of producing a practical, cost-effective leishmaniasis vaccine capable of protecting both humans and dogs against multiple Leishmania species.